Skip to main content

Table 2 Number of patient-years of follow-up by population and treatment cohort in psoriasis patients with self-reported PsA enrolled in PSOLAR

From: Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

 UstekinumabTNF inhibitorsaInfliximabEtanerceptAdalimumabNon-biologic/MTXbNon-biologic/non-MTXcAlld
Overall population
 N6281413258481674982082401
 Patient-years20094101756143219133666947244
Duration of follow-up, years
 Mean ± SD5.0 ± 1.94.9 ± 2.24.7 ± 2.34.8 ± 2.35.0 ± 2.14.2 ± 2.23.7 ± 2.64.8 ± 2.2
 Median5.165.164.705.165.354.323.505.11
Incident population
 N32648664130292982081163
 Patient-years90410821252916653666943101
Duration of follow-up, years
 Mean ± SD5.4 ± 1.95.4 ± 2.05.3 ± 2.05.5 ± 2.05.4 ± 2.04.2 ± 2.23.7 ± 2.65.0 ± 2.2
 Median5.715.615.675.645.594.323.505.40
Bionaive population
 N5616714728198208532
 Patient-years144419351802043666941626
Duration of follow-up, years
 Mean ± SD4.4 ± 2.05.2 ± 2.04.6 ± 1.85.6 ± 2.24.8 ± 1.94.2 ± 2.23.7 ± 2.64.4 ± 2.3
 Median4.665.524.396.175.144.323.504.70
  1. The biologic user cohort includes patients who are on the cohort defining biologic at entry or start the biologic after entry; previous use or current exposure is allowed for MTX, but not for other systemic immunomodulators
  2. MTX methotrexate; PsA, psoriatic arthritis; PSOLAR, Psoriasis Longitudinal Assessment and Registry; SD, standard deviation
  3. aTumor necrosis factor (TNF) inhibitors include infliximab, etanercept, and adalimumab
  4. bThe non-biologic/MTX cohort includes patients who are receiving MTX at entry or start methotrexate during the registry and haven’t been exposed to other systemic immunomodulators previously or concurrently
  5. cNon-biologic, non-MTX therapies may include, but are not limited to, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, oral corticosteroids, systemic retinoids, psoralen plus ultraviolet (UV), or UVB phototherapy. The non-biologic/non-MTX cohort includes patients who are receiving other systemic immunomodulators (including cyclosporine, tacrolimus, mycophenolate mofetil, other immunomodulators, and oral corticosteroids) at entry or start other immunomodulators after registry and who haven’t been exposed to MTX previously or concurrently; patients who receive only topical and/or phototherapy at/after registry entry are also in this cohort
  6. dIncludes “Other biologics” group (n = 54); data not shown